Answer
In patients with metastatic breast cancer receiving sacituzumab govitecan alone at 10 mg/kg, population pharmacokinetic analysis estimated median elimination half-lives of 155 hours for sacituzumab govitecan and 21.5 hours for free SN-38.
Sources for this answer
- Trodelvy 180 mg powder for concentrate for solution for infusionGilead Sciences Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked